SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001437749-17-017396
Filing Date
2017-10-20
Accepted
2017-10-20 16:12:34
Documents
5
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-K/A avir20170630_10ka.htm 10-K/A 324881
2 EXHIBIT 31.3 ex_96685.htm EX-31.3 11484
3 EXHIBIT 31.4 ex_96686.htm EX-31.4 11624
4 EXHIBIT 32.3 ex_96687.htm EX-32.3 4806
5 EXHIBIT 32.4 ex_96688.htm EX-32.4 5716
  Complete submission text file 0001437749-17-017396.txt   359850
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Filer) CIK: 0000072444 (see all company filings)

IRS No.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-K/A | Act: 34 | File No.: 001-35285 | Film No.: 171147144
SIC: 2836 Biological Products, (No Diagnostic Substances)